Literature DB >> 17909551

Is cetuximab active in patients with cisplatin-refractory squamous cell carcinoma of the head and neck?

James A Bonner1, Kimberly S Keene.   

Abstract

Entities:  

Year:  2007        PMID： 17909551     DOI： 10.1038/ncponc0962

Source DB:  PubMed          Journal:  Nat Clin Pract Oncol        ISSN： 1743-4254


× No keyword cloud information.
  2 in total

1.  TLR3 agonists improve the immunostimulatory potential of cetuximab against EGFR+ head and neck cancer cells.

Authors:  Chwee Ming Lim; Ryan Stephenson; Andres M Salazar; Robert L Ferris
Journal:  Oncoimmunology       Date:  2013-04-29       Impact factor: 8.110

2.  Cetuximab Reconstitutes Pro-Inflammatory Cytokine Secretions and Tumor-Infiltrating Capabilities of sMICA-Inhibited NK Cells in HNSCC Tumor Spheroids.

Authors:  Stephan Klöss; Nicole Chambron; Tanja Gardlowski; Sandra Weil; Joachim Koch; Ruth Esser; Elke Pogge von Strandmann; Michael A Morgan; Lubomir Arseniev; Oliver Seitz; Ulrike Köhl
Journal:  Front Immunol       Date:  2015-11-02       Impact factor: 7.561
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.